Strategic leadership changes and corporate consolidations are underway. Novartis named a new CFO, Pranav Mehta, to steer financial strategy amid evolving company goals. Waters Corporation announced an agreement to combine with BD's Biosciences & Diagnostic Solutions business in a $17.5 billion Reverse Morris Trust transaction, creating a leading entity in regulated high-volume life science testing with expanded market reach and complementary technologies. These moves exemplify ongoing restructuring and partnerships intended to capture growth opportunities and streamline innovation pipelines across biotech and diagnostics.